Below you will find a few sample entries from each of the eight BioWorld Snapshot categories. This page is meant to give you an idea of the types of data contained in the Snapshots. The full Snapshots will contain dozens of records, and are updated daily.
|
|
COMMENCED TRADING -
August 2009 |
INITIAL OFFERINGS | |
Company |
Date Filed |
Date Comm. |
Shares/Units (M) |
Price |
Shares Out (M) |
Gross (M) |
Cumberland Pharmaceuticals Inc. (CPIX) |
5/1/07 |
8/12/09 |
5S |
$17 |
17.1 |
$85 |
D-Pharm Ltd. (Israel; TASE:DPRM) |
8/17/09 |
8/17/09 |
1.7S |
$4.50 |
N/A |
NIS28 ($7.6) |
|
FOLLOW-ON OFFERINGS -
August 2009 | |
Company |
Date Filed |
Date Comm. |
Shares/Units (M) |
Price |
Gross (M) |
Ariad Pharmaceuticals Inc. (ARIA) |
8/4/09 |
8/4/09 |
21.9S |
$1.75 |
$38.33 |
Avanir Pharmaceuticals Inc. (AVNR) |
8/27/09 |
8/27/09 |
4.5S |
$2.34 |
$10.6 |
AVI BioPharma Inc. (AVII) |
8/20/09 |
8/20/09 |
24.3S and W for 9.7S |
$1.42 |
$34.5 |
|
PUBLIC COMPANIES -
August 2009 |
|
Company (Symbol) |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
Amount Raised (US$M) |
Amarin Corp. (Ireland; AMRN) |
Private placement of convertible bridge loan notes |
N/A |
$3 |
Auxilium Pharmaceuticals Inc. (AUXL) |
Revolving line of credit |
N/A |
$30 |
BioSante Pharmaceuticals Inc. (BPAX) |
Registered direct offering |
6S and W for 2.4S |
$12 |
|
PRIVATE COMPANIES - August
2009 | |
Company |
Location |
Date |
Amount Raised (US$M) |
Round |
Acetylon Pharmaceuticals Inc. |
Cambridge, Mass. |
8/7 |
$7.25 |
First |
Adamas Pharmaceuticals Inc. |
Emeryville, Calif. |
8/18 |
$40 |
Fourth |
AdvanDx |
Woburn, Mass. |
8/18 |
$8 |
Third |
|
COMPLETED MERGERS AND ACQUISITIONS -
August 2009 |
Company Acquired |
Acquired By Or Merged With |
Date Announced |
Date Completed |
Value (M) |
Terms/Details |
Arana Therapeutics Ltd. (Australia; LSE:AAHX) |
Cephalon Inc. (CEPH) |
2/27/09 |
8/11/09 |
A$318 ($207) |
Cephalon acquired Arana for A$1.40 per share, a 70% premium |
Medarex Inc. (MEDX) |
Bristol-Myers Squibb Co. |
7/23/09 |
8/27/09 |
$2.4B |
Bristol-Myers bought Medarex for $16 per share |
Monogram Biosciences Inc. (MGRM) |
Laboratory Corp. of America Holdings (NYSE:LH) |
6/23/09 |
8/4/09 |
$155 |
LabCorp acquired Monogram for $4.55 a share, a 170% premium |
|
|
Biotech Company |
Pharma Company |
Type/Product Area |
Terms/Details |
Addrenex Pharmaceuticals |
Dream Pharma Ltd. (UK) |
Exclusive partnership for the right to manufacture, market and sell Clonicel in Korea |
Clonicel is being developed for both the treatment of hypertension and attention deficit hyperactivity disorder |
Celentyx Ltd. |
Meiji Seika Kaisha Ltd. (Japan) |
Drug reprofiling agreement aimed at seeking alternative development paths for drug candidates previously discontinued or deprioritized for reasons other than safety |
Meiji will use Celentyx's Novel Clinical Indication Profiling technology |
Forest Laboratories Inc. (NYSE:FRX) |
AstraZeneca plc (UK) |
Ex-North American partnership for late-stage antibiotic ceftaroline |
Specific financial terms were not disclosed; AstraZeneca will assume responsibility for regulatory and commercial activities of ceftaroline in Europe |
BIOTECH PRODUCTS 2009 |
Company |
Product |
Marketer |
Indication (U.S. Approval Date; Month/Day) |
Allos Therapeutics Inc. |
Folotyn |
Allos |
Peripheral T-cell lymphoma (9/25) |
Centocor Ortho Biotech Inc. (unit of Johnson & Johnson) |
Stelara |
Centocor |
Moderate to severe plaque psoriasis (9/25) |
Novartis AG |
Valturna |
Novartis |
High blood pressure patients not adequately controlled on aliskiren or angiotensin receptor blocker monotherapy and as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals (9/18) |
|
|
Company |
Company |
Type/Product Area |
Terms/Details |
Alnylam Pharmaceuticals Inc. (ALNY) |
Tekmira Pharmaceuticals Corp. (Canada; TSX:TKM) |
Research collaboration focused on the discovery of novel cationic lipids and lipid nanoparticles for the systemic delivery of RNAi therapeutics |
Alnylam will receive exclusive rights to all new inventions as well as rights to sublicense any resulting intellectual property to Alnylam's current and future partners |
AlphaRx Inc. (Canada; OTC BB:ALRX) |
Venturepharm Group (China; BE:VNL) |
Collaboration to establish a drug development center in China, with the aim of expediting product development for the Chinese market |
AlphaRx will locate the facility in Venturepharm's development complex but will be responsible for all of its own product development costs and will retain intellectual property rights relating to any developed products |
Antisoma plc (UK; LSE:ASM) |
Bryan Oncor Inc. |
Agreement to assign all rights for P2045 to Bryan Oncor |
The product has completed a Phase I trial in non-small-cell lung cancer |
Cellceutix Corp. (OTC BB:CTIX) |
Girindus America Inc. |
Agreement for the manufacture of Kevetrin active pharmaceutical ingredient |
Terms were not disclosed; the material will be used to do the last animal studies needed for the filing of an investigational new drug application |
Symbol |
Name |
Last |
Market Capitalization |
Shares Outstanding |
AMGN |
Amgen |
59 |
59,913,143,000 |
1,015,477,000 |
GILD |
Gilead Sciences |
45.3 |
40,963,036,200 |
904,261,300 |
CELG |
Celgene |
54.99 |
25,219,652,045 |
458,622,500 |
GENZ |
Genzyme |
55.22 |
14,926,430,178 |
270,308,400 |
|
|
|
| |
